Darolutamide Extends Survival in Metastatic Prostate Cancer - NCI

Adding darolutamide (Nubeqa) to ADT and docetaxel improves survival in hormone-sensitive metastatic prostate cancer, results from the ARASENS trial show.

Efficacy and safety of darolutamide in Japanese patients with

View of Darolutamide (Nubeqa) Canadian Journal of Health

Bayer expands global clinical program for darolutamide in prostate

PDF) 223P Overall survival (OS) results of phase III ARAMIS study

View of Darolutamide (Nubeqa) Canadian Journal of Health

Darolutamide combination therapy improves overall survival in

Darolutamide and Survival in Metastatic, Hormone-Sensitive

Androgen-targeted therapy in men with prostate cancer: evolving

Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab

FDA Expands Nubeqa Indications for Prostate Cancer - GoodRx

Abiraterone acetate plus prednisolone with or without enzalutamide

Clinical Development of Darolutamide: A Novel Androgen Receptor

Darolutamide and Survival in Metastatic, Hormone-Sensitive

Prostate cancer - The Lancet